// App-Quantinova.ai

11 : Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Anders Bjartell

  • Byung Ha Chung

  • Andrea Juliana Pereira de Santana Gomes

  • Robert Given

  • lvaro Jurez Soto

  • Axel Stuart Merseburger

  • Mustafa Ozguroglu

  • Hirotsugu Uemura

  • Dingwei Ye

  • Spyros Triantos

  • Suneel Mundle

  • Sharon Anne McCarthy

  • Julie S. Larsen

  • Weili Sun

  • Katherine Bevans

  • Ke Zhang

  • Nibedita Bandyopadhyay

  • Neeraj Agarwal

Medical Centers

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • Guys, Kings and St. Thomas Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

  • Skane University Hospital Malmo, Lund University, Malmo, Sweden

  • Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea

  • Liga Norte Riograndense Contra o Cncer, Natal, Brazil

  • Urology of Virginia, Eastern Virginia Medical School, Norfolk, VA

  • Hospital Universitario de Jerez de la Frontera, Cadiz, Spain

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey

  • Niigata University School of Medicine, Niigata, Japan

  • Fudan University Shanghai Cancer Center, Shanghai, China

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, LLC, Horsham, PA

  • Janssen Research & Development, San Diego, CA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

Locations

  • Canada

  • United Kingdom

  • Sweden

  • Republic of South Korea

  • Brazil

  • United States

  • Spain

  • Germany

  • Turkey

  • Japan

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

Phase

  • NA

Study Id's

  • NCT02489318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved